These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 22642867

  • 1. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
    Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Aerts JG.
    Curr Med Res Opin; 2012 Jul; 28(7):1079-87. PubMed ID: 22642867
    [Abstract] [Full Text] [Related]

  • 2. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [Abstract] [Full Text] [Related]

  • 3. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study.
    Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B.
    Curr Med Res Opin; 2011 May; 27(5):987-94. PubMed ID: 21385113
    [Abstract] [Full Text] [Related]

  • 4. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
    Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
    Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611
    [Abstract] [Full Text] [Related]

  • 5. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I, Laplaige P, Vey N, Asselain B, Urbieta M.
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

  • 7. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Jan; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 8. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 9. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
    Hess G, Hill J, Clough J, Hulnick S, Nordyke RJ.
    Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
    [Abstract] [Full Text] [Related]

  • 10. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 11. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B, van de Werf PR, Melissant CF, Brok RG.
    Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
    [Abstract] [Full Text] [Related]

  • 12. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 13. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 14. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 16. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T, Kindler M, Lange O, Vehling-Kaiser U, Kuhn A, Hellebrand E.
    Curr Med Res Opin; 2014 Sep 03; 30(9):1813-20. PubMed ID: 24849527
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH.
    Clin Ther; 2016 Jan 01; 38(1):122-135.e6. PubMed ID: 26730453
    [Abstract] [Full Text] [Related]

  • 18. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.
    Med Oncol; 2012 Sep 01; 29(3):2291-9. PubMed ID: 22081263
    [Abstract] [Full Text] [Related]

  • 19. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Sep 01; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Sep 01; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.